Pfizer, Merck immunotherapy combo delays kidney cancer progression
Bavencio, which was developed together with Pfizer, was found to delay the progression of kidney cancer when used with Pfizer ’s Inlyta
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Immunotherapy | Kidney Cancer | Merck | Pfizer | Urology & Nephrology